Glens Falls Hospital

100 Park Street, Glens Falls, NY 12801 518.926.1000

Clinical Trials


P = Pharmacy
CTSU= NCI Cancer Trials Support Unit
V = Vermont Cancer Center


Updated 6-16-15



N B51  

  • A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (Pre-Activation Only) - On Hold

PUMA NER 1301          

  • (NALA) A Study of Neratinib Plus Capecitabine vs. Lapatinib Plus Capecitabine in Patients with Her2+ Metastatic Breast Ca who Have Received >/= 2 Prior Her2-Directed Regimens in the Metastatic Setting


  • A randomized double-blind, placebo- controlled study of ribociclib in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment



CTSU A021202  

  • Prospective randomized phase II trial of Pazopanib vs. placebo in patients with progressive carcinoid tumors



C 80702  

  • A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

CTSU S0820  

  • A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)


Head and Neck:


  • A Phase III Study of Postoperative Radiation Therapy (IMRT) =/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer


CTSU A041202  Â 

  • A randomized Phase III Study of Bendamustine plus Rituximab vs Ibrutinib plus Rituximab vs Ibrutinib alone in Untreated Older Patients (≥ 65 years of age) with Chronic Lymphocytic Leukemia (CLL)


CTSU  Â Â Â  E1912 

  • A Randomized Phase III Study of Ibrutinib(PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)


Lung: SCLC Limited:
C 30610

  • Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide



CTSU E1411  

  • Phase II 4-Arm Study In Patients 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV LR)



CTSU E2905  

  • Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia




  •  A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma


CTSU S1216  

  • A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide inPatients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer




CTSU S0931  

  • EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study



P Registry

  • Breast Cancer Collaborative Registry (BCCR) for patients who have breast cancer that has been recently diagnosed, have a history of breast cancer, or are at high risk of developing breast cancer, or because relatives have been diagnosed with breast cancer.

P Registry

  • informCLLâ„¢: A Disease Registry for Patients with Chronic Lymphocytic Leukemia

P Registry

  • Celgene Corporation Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry


Treatment Protocols

Glens Falls Hospital
Pruyn Pavilion
Research Office
Phone: (518) 926-6644
Fax: (518) 926-1954

Staff Directory


Robert W. Sponzo, M.D.
Aqeel Gillani, M.D.
John Stoutenburg, M.D.
Eric Pillemer, M.D.
Darci Gaiotti-Grubbs, M.D.
Mark Hoffman, M.D.

Alex Frank, M.D.


Clinical Research Support:

Beth Ann Brundage, RN, OCN
Nannette Oberhelman, CCRP
Jean VanAuken, RPA-C